LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) —


The Portnoy Law Firm


advises Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney


Lesley F. Portnoy


, by phone 310-692-8883 or


email


: [email protected], to discuss their legal rights, or


click here


to join the case via


www.portnoylaw.com


. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

After the market closed on July 28, 2021, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer’s and Parkinson’s Disease patients relative to a placebo. On July 29, 2021 Annovis’ stock price declined by $65.94 per share, or approximately 60.25%, on this news from $109.44 per share to close at $43.50 per share.

Please visit our


website


to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.

Admitted CA and NY Bar



[email protected]



310-692-8883

www.portnoylaw.com

Attorney Advertising